Skip to main content

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting · Phase 3 · NCT05578976

Conditions: Diffuse Large B-Cell Lymphoma

At a glance

Research payments reported, 2025
$3.4M
U.S. investigators named
58
Sites paid
57
Planned or actual enrollment
900

About the trial

Sponsor
Genmab
Tested
Epcoritamab (drug), Cyclophosphamide (drug), Rituximab (drug), Vincristine (drug), Doxorubicin (drug), Prednisone (drug)
Dates
Started 2023-02-08; completion 2029-12
Results posted
Not yet

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in groups called treatment arms. Participants will receive epcoritamab combined with R-CHOP, follo…

From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $3.4M in research payments for this study in 2025 (365 payments).

Products named: Epkinly

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.